Yuliya Naumchuk

Yuliya Naumchuk

Auto-generated profile, based on publicly available information

Yuliya Naumchuk

Vision Research Center, Department of Ophthalmology, University of Missouri - Kansas City, School of Medicine, 2411 Holmes St., Kansas City, MO 64108, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAndrew J. Payne
Andrew J. Payne
SKSimon Kaja
Simon Kaja
YNYuliya Naumchuk
Yuliya Naumchuk
NKNancy Kunjukunju
Nancy Kunjukunju
Peter KoulenPeter Koulen
Peter Koulen
The molecular pathways contributing to visual signal transduction in the retina generate a high energy demand that has functional and structural consequences such as vascularization and high metabolic rates contributing to oxidative stress. Multiple signaling cascades are involved to actively regulate the redox state of the retina. Age-related processes increase the oxidative load, resulting in chronically elevated levels of oxidative stress and reactive oxygen species, which in the retina ultimately result in pathologies such as glaucoma or age-related macular degeneration, as well as the neuropathic complications of diabetes in the eye. Specifically, oxidative stress results in deleterious changes to the retina through dysregulation of its intracellular physiology, ultimately leading to neurodegenerative and potentially also vascular dysfunction. Herein we will review the evidence for oxidative stress-induced contributions to each of the three major ocular pathologies, glaucoma, age-related macular degeneration, and diabetic retinopathy. The premise for neuroprotective strategies for these ocular disorders will be discussed in the context of recent clinical and preclinical research pursuing novel therapy development approaches.

1 December 2013 in Experimental Neurology
Verified
Journal Article
Closed access
APAndrew J. Payne
Andrew J. Payne
BGBryan C. Gerdes
Bryan C. Gerdes
YNYuliya Naumchuk
Yuliya Naumchuk
AMAudrey E. McCalley
Audrey E. McCalley
SKSimon Kaja
Simon Kaja
Peter KoulenPeter Koulen
Peter Koulen

1 September 2015 in Experimental Eye Research
Verified
Journal Article
Closed access
SKSimon Kaja
Simon Kaja
APAndrew J. Payne
Andrew J. Payne
YNYuliya Naumchuk
Yuliya Naumchuk
DLDeborah Levy
Deborah Levy
DZDanish H. Zaidi
Danish H. Zaidi
Peter KoulenPeter Koulen
Peter Koulen

1 March 2015 in Experimental Neurology
Verified
Journal Article
Closed access
SKSimon Kaja
Simon Kaja
APAndrew J. Payne
Andrew J. Payne
KPKrupa R. Patel
Krupa R. Patel
YNYuliya Naumchuk
Yuliya Naumchuk
Peter KoulenPeter Koulen
Peter Koulen

1 January 2014 in Vision Research
Verified
Journal Article
Closed access
SKSimon Kaja
Simon Kaja
YNYuliya Naumchuk
Yuliya Naumchuk
SGStephanie L. Grillo
Stephanie L. Grillo
PBPriscilla K. Borden
Priscilla K. Borden
PKPeter Koulen
Peter Koulen

1 April 2015 in Clinical Ophthalmology
Verified
Journal Article
Open access
SKSimon Kaja
Simon Kaja
ASAnna Shah
Anna Shah
SHShamim Haji
Shamim Haji
KPKrishna B Patel
Krishna B Patel
YNYuliya Naumchuk
Yuliya Naumchuk
Peter KoulenPeter Koulen
Peter Koulen
The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision.